S
ADAP

SignatureFD’s Adaptimmune Therapeutics ADAP Stock Holding History

SignatureFD’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,620
Closed -$6.29K – 3302
2024
Q3 		$6.29K Buy
+6,620
New +$7.51K ﹤0.01% 2503
2024
Q2 		– Sell
-2,037
Closed -$3.22K – 3123
2024
Q1 		$3.22K Buy
+2,037
New +$2.46K ﹤0.01% 2670
2023
Q1 		– Sell
-373
Closed -$545 – 3277
2022
Q4 		$545 Sell
373
-2,812
-88% -$4.55K ﹤0.01% 3091
2022
Q3 		$3K Buy
3,185
+2,413
+313% +$4.43K ﹤0.01% 2597
2022
Q2 		$1K Sell
772
-355
-31% -$610 ﹤0.01% 2864
2022
Q1 		$2K Sell
1,127
-3,103
-73% -$8.38K ﹤0.01% 2758
2021
Q4 		$16K Buy
4,230
+23
+0.5% +$105 ﹤0.01% 1869
2021
Q3 		$22K Buy
4,207
+3,983
+1,778% +$17.9K ﹤0.01% 1709
2021
Q2 		$1K Sell
224
-720
-76% -$3.5K ﹤0.01% 2663
2021
Q1 		$5K Buy
944
+720
+321% +$4.12K ﹤0.01% 2109
2020
Q4 		$1K Buy
+224
New +$1.22K ﹤0.01% 2370
2020
Q3 		– Sell
-373
Closed -$4K – 2587
2020
Q2 		$4K Buy
+373
New +$2.34K ﹤0.01% 1857

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SignatureFD's ADAP Position: Q4 2024 in Review

SignatureFD sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 6,620 shares — an estimated $6.29K sold.

SignatureFD first reported a position in ADAP in Q2 2020 and held it in 12 quarters. The position peaked at $22K in Q3 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • SignatureFD reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • SignatureFD sold 6,620 Adaptimmune Therapeutics shares in Q4 2024, an estimated $6.29K.
  • SignatureFD first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 12 quarters.
  • SignatureFD's Adaptimmune Therapeutics position peaked at $22K in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on SignatureFD's 13F filing for Q4 2024, filed 10 Feb 2025.